摘要
目的探讨多西紫杉醇联合顺铂(DDP)治疗晚期非小细胞肺癌(NSCLC)的临床疗效和不良反应。方法将晚期NSCLC患者120例随机分成实验组(60例)和对照组(60例)。实验组:多西紫杉醇75 mg/m2,静脉滴注,第1天;DDP 80 mg/m2,静脉滴注,分3 d,21 d为1个周期。对照组:长春瑞宾25 mg/m2,静脉滴注,第1、8天,DDP 80 mg/m2,静脉滴注,分3 d,21 d为1个周期。对其有效率、中位疾病进展时间(TTP)、1年生存率和不良反应进行评价。结果120例入组患者中有113例可评价疗效,实验组和对照组的有效率分别为38.6%、35.7%,中位TTP分别为6.2、7.7个月,1年生存率分别为47.4%、37.5%,两组比较差异均有统计学意义(均P<0.05)。实验组Ⅲ、Ⅳ度中性粒细胞减少及Ⅲ、Ⅳ度恶心呕吐的发生率明显低于治疗组(P<0.05),两组其余不良反应相似。结论在治疗晚期NSCLC方面,多西紫杉醇联合顺铂方案与长春瑞宾联合顺铂方案疗效相似,但多西紫杉醇联合顺铂的不良反应较低,患者更易耐受,值得临床推广。
Objective To investigate the effects and side effects of Docetaxel combined with Cisplatin（DDP） in the treatment of the advanced stage of non-small cell lung cancer（NSCLC）.Methods 120 patients with the advanced stage of NSCLC are randomly divided into experimental group（60 cases） and control group（60 cases）.Experimental group： Docetaxel 75 mg/m2,intravenous drip,d1;DDP 80 mg/m2,intravenous drip,3 d,21 d for one cycle.Control group： Vinorelbine 25 mg/m2,intravenous infusion,d1 and d8,DDP 80 mg/m2,intravenous drip,3 d,21 d for one cycle.The efficiency,the median time to progression（TTP）,1-year survival rate and adverse reactions were evaluated.Results Experimental group was Ⅲ,Ⅳ degree of neutropenia and the Ⅲ,Ⅳ degree of nausea and vomiting were significantly lower than the experimental group（P 0.05）;two other adverse reactions were similar.Conclusion In periods of NSCLC,the efficacy between Docetaxel combined with DDP and Vinorelbine combined with DDP are similar,but the adverse reactions of Docetaxel combined with DDP are low,so the patients are more tolerance,and the methods are worth of promotion.
出处
《中国医药导报》
CAS
2012年第3期81-83,共3页
China Medical Herald
关键词
非小细胞肺癌
多西紫杉醇
顺铂
Non-small cell lung cancer
Docetaxel
Cisplatin
